Search results
Showing 136 to 150 of 2172 results for technology appraisal
Evidence-based recommendations on implantable cardioverter defibrillators and cardiac resynchronisation therapy for people with ventricular arrhythmias or heart failure
Evidence-based recommendations on dapagliflozin for treating chronic kidney disease in adults.
Rozanolixizumab for treating antibody-positive generalised myasthenia gravis [ID5092]
In development Reference number: GID-TA10994 Expected publication date: TBC
Eltrombopag for treating chronic immune thrombocytopenia (TA293)
Evidence-based recommendations on eltrombopag (Revolade) for treating chronic immune thrombocytopenia in adults.
NICE is unable to make a recommendation on ciltacabtagene autoleucel (Carvykti) for treating relapsed or refractory multiple myeloma in adults. This is because Janssen withdrew its evidence submission for the appraisal. We will review this decision if the company decides to make a submission.
Show all sections
Sections for TA889
Erlotinib monotherapy for maintenance treatment of non-small-cell lung cancer (TA227)
Evidence-based recommendations on erlotinib (Tarceva) for the maintenance treatment of non-small-cell lung cancer in adults.
NICE health technology evaluation topic selection: the manual (PMG37)
This manual sets out the process for deciding how topics are identified, selected and routed for NICE guidance developed by the Centre for Health Technology Evaluation (CHTE). This includes diagnostics, highly specialised technologies, interventional procedures, medical technologies and technology appraisal guidance
Evidence-based recommendations on dasatinib (Sprycel), nilotinib (Tasigna) and high-dose imatinib (Glivec) for treating imatinib-resistant or intolerant chronic myeloid leukaemia in adults.
Evidence-based recommendations on nintedanib (Vargatef) for treating locally advanced, metastatic or locally recurrent non-small-cell lung cancer in adults.
Fosdenopterin for treating molybdenum cofactor deficiency type A (terminated appraisal) (TA1078)
NICE is unable to make a recommendation on fosdenopterin (Nulibry) for treating molybdenum cofactor deficiency type A in people of all ages. This is because Sentynl Therapeutics has withdrawn from the appraisal.
Show all sections
Sections for TA1078
Evidence-based recommendations on certolizumab pegol (Cimzia) for treating severe active rheumatoid arthritis in adults who have had a tumour necrosis factor-alpha inhibitor.
Awaiting development Reference number: GID-TA10438 Expected publication date: TBC
Evidence-based recommendations on abemaciclib (Verzenios) with fulvestrant for hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy in adults.
Bimekizumab for treating moderate to severe hidradenitis suppurativa (terminated appraisal) (TA1028)
NICE is unable to make a recommendation about the use in the NHS of bimekizumab (Bimzelx) for treating moderate to severe hidradenitis suppurativa in adults. This is because UCB Pharma withdrew from the appraisal.
Show all sections
Sections for TA1028